Category: Covid-19

Page 20«..10..19202122..3040..»

FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases – University of Minnesota Twin Cities

June 16, 2024

Though the US Food and Drug Administration (FDA) last week recommended that vaccine companies switch to the JN.1 variant for updated shots for the fall, yesterday it urged companies to focus on the KP.2 lineage if possible, based on recent shifts and a national rise in cases.

On June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held off on recommending the KP.2 offshoot of JN.1, partly due to uncertainties about further evolution of SARS-CoV-2 strains. The group was also concerned about the availability of Novavax, which as a protein-based vaccine that has a longer production timeline and would not be able to switch to the more specific KP.2 lineage.

Shortly after, the FDA accepted the advisers' advice but said it would continue to monitor the safety and efficacy of COVID-19 vaccines, along with the evolution of the virus. In its latest variant proportion update, the Centers for Disease Control and Prevention (CDC) reported another jump in KP.3 proportions, along with a further rise in KP.2 viruses and a steady decline in the JN.1 parent lineage.

The two rising offshoots have the mutations that are thought to make them more evasive to immunity from earlier infection or previous vaccination.

In its statement yesterday, the FDA said that, based on the latest data, including rises in COVID-19 activity in some parts of the country, the preferred vaccine lineage is KP.2, and that a switch from the original JN.1 recommendation is intended to ensure that 2024-25 COVID vaccines more closely match circulating strains.

"The agency does not anticipate that a change to KP.2 will delay the availability of the vaccines for the United States," the FDA said. mRNA vaccines have a shorter production timeline and appear well poised to incorporate the change.

Novavax, which produces the protein-based option, said its vaccine provides broad cross-neutralization against a range of JN.1 descendant viruses, including KP.2 and KP.3. It also said the vaccine produces conserved T-cell responses against a range of JN.1 offshoots.

"These responses indicate that our vaccine technology induces broadly neutralizing responses against multiple variant strains, including to circulating forward drift variants," it said in a statement, which was first posted on June 5, then updated on June 10.

The company said it expects to have the vaccine ready for commercial delivery in September, pending FDA authorization.

In its data updates today, the CDC reported more rises in its early COVID indicators, which have shown a small uptick over the past few weeks from very low levels. The percentage of tests with positive results rose slightly and is highest in the western region that includes Arizona, California, Hawaii, and Nevada.

Emergency department visits from COVID were up modestly. Hawaii has the highest level, which is listed as moderate. Other states are at the minimal level or don't have enough data for analysis.

Earlier this week, the Hawaii State Department of Health urged the public to be vigilant because of high COVID levels, which are at the red level, meaning they are at high levels compared to historic trends. "This high level means that recommended precautions are more important for reducing risk," it said.

In a respiratory virus illness snapshot today, the CDC estimated that COVID levels are growing or likely growing in 34 states or territories, declining in 1, with the trend uncertain in 14. "An increasing proportion of the variants that cause COVID-19 are projected to be KP.3 and LB.1," the agency said. LB.1 is another JN.1 offshoot showing rising proportions.

Hawaii's health department urged people to be up to date with their recommended vaccine doses, especially seniors, to stay home when sick and take extra precautions in the household, to wear a well-fitted mask indoors with other people, and to test if having symptoms.

CDC wastewater tracking show that overall levels are low, but up sharply in the West. Meanwhile, the latest data from WastewaterSCAN, a national wastewater monitoring system based at Stanford University in partnership with Emory University, suggest that COVID levels are in the high category nationally and in the South and Northeast, with concentrations medium and on an upward trend over the past 3 weeks. It put the Midwest and the West in the medium category.

Read more:

FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases - University of Minnesota Twin Cities

Authorities: Paramus man obtained COVID-19 relief loans for business that closed before pandemic – Miami County Republic

June 16, 2024

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Go here to see the original:

Authorities: Paramus man obtained COVID-19 relief loans for business that closed before pandemic - Miami County Republic

Trumps Anti-Vaccine Problem – The New York Times

June 16, 2024

Former President Donald Trumps chaotic and denial-filled response to the Covid-19 pandemic turned off independent voters and arguably cost him the 2020 presidential election.

Four years later, a different aspect of his handling of the pandemic has emerged as a sensitive subject with another slice of the electorate: his own die-hard supporters.

Over the past year, as I have listened to Trumps devotees sing his praises all over the country, I have noticed that theyve shown a rare willingness to criticize Trump over the speedy development of the Covid-19 vaccines, which he had celebrated as one of his administrations major successes. The vaccines, a scientific breakthrough, have been given to 270 million Americans and are estimated to have saved millions of lives.

Im not real thrilled with the accelerated rollout of the vaccine, said Amaris Angell, the owner of a recently shuttered food truck business, who went to see Trump in Las Vegas on Sunday. He still seems to be proud of himself for that.

Its poison, Nanette Finazzo said of the Covid vaccine.

I dont believe in the shots, Jeanette Reineck said as she waited for Trump to take the stage on Sunday. Never have.

The anti-vaccine sentiment coursing through Trumps fan base has not yet emerged as a major political liability for the former president. Most voters Ive spoken to quickly excuse Trump for listening to the people around him at a time when no one understood much about Covid. And attempts by Ron DeSantis, the Florida governor, to attack him over his handling of the pandemic during the primary and caucus season never really caught on.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

Read the original here:

Trumps Anti-Vaccine Problem - The New York Times

KP.3, the new COVID variant is here: What we know about it till now – The Times of India

June 16, 2024

KP.3, the new variant of COVID, is currently responsible for over 25% of all COVID cases in the US as per the data released by the Centers for Disease Control and Prevention. It is overtaking the previously dominant JN.1 variant. Apart from this, other variants of the FLiRT group of COVID variants are also driving COVID cases in the US. What is the KP.3 COVID variant?KP.3 is a "sublineage of the JN.1 lineage, which comes from the Omicron variant, CDC spokesperson Rosa Norman. KP.3 evolved from JN.1, which was the major viral lineage circulating since December 2023. It is very similar to JN.1 and only has two changes in spike compared to JN.1, he told the USA Today. KP.2, another major variant of COVID, currently accounts for 22.5% of COVID cases in the US. What are the symptoms seen in the KP.3 COVID variant?COVID-19, caused by the SARS-CoV-2 virus, presents a wide array of symptoms, ranging from mild to severe. Common symptoms include fever, dry cough, and fatigue. Many patients also report a loss of taste or smell, which can be a distinguishing feature of the virus. Respiratory symptoms such as shortness of breath and chest pain can occur, especially in more severe cases. Muscle or joint pain, headaches, and sore throat are frequently reported. Gastrointestinal symptoms like nausea, vomiting, and diarrhea are also observed, highlighting the virus's ability to affect multiple body systems. Some individuals experience skin manifestations, including rashes and discoloration of fingers or toes. The severity of symptoms varies widely; while some individuals remain asymptomatic, others develop life-threatening complications such as pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. Do not ignore COVID signs in kidsChildren and adolescents tend to experience milder symptoms compared to adults. However, a rare but serious condition known as multisystem inflammatory syndrome in children (MIS-C) has been linked to COVID-19. High-risk groups, including the elderly and those with underlying health conditions such as diabetes, heart disease, and compromised immune systems, are more likely to develop severe symptoms and complications. Early detection and isolation are crucial to prevent the spread of COVID-19. Testing, vaccination, and adherence to public health measures remain vital in managing and controlling the pandemic. Experts say, vaccines do protect against KP.3 variant. Preventing COVID-19 infection involves several key practices. Wear masks in public spaces to reduce the spread of respiratory droplets. Maintain physical distancing, keeping at least six feet away from others. Practice good hand hygiene by washing hands frequently with soap and water for at least 20 seconds, or using hand sanitizer with at least 60% alcohol. Avoid large gatherings and poorly ventilated areas. Stay informed about COVID-19 vaccines and get vaccinated when eligible. Follow public health guidelines, such as staying home when feeling unwell and adhering to local restrictions and recommendations. These measures collectively help reduce the risk of infection.

View post:

KP.3, the new COVID variant is here: What we know about it till now - The Times of India

Opinion | Debating Covids Origins: A Lab or a Market? – The New York Times

June 16, 2024

To the Editor:

Re Why Covid Probably Started in a Lab, by Alina Chan (Opinion guest essay, June 9):

Dr. Chan makes a case for a laboratory origin of Covid-19. Richly illustrated with animated graphics online, the text proposes five main arguments to accuse a team led by Dr. Shi Zhengli, a scientist based in Wuhan, China, of having created the virus causing Covid in her lab, letting it leak, and hiding information linking the pandemics origin to her work. Dr. Chan further implied that Dr. Shis collaborators could also be hiding incriminating evidence.

These accusations are very serious, yet the case made by Dr. Chan rests entirely on speculation. Critical facts are ignored, such as the presence of live wild animals involved in the emergence of SARS in the market where many of the first people known to have gotten Covid worked or shopped. In my view, proper scientific analyses, which a majority of experts agree support a natural origin, are misrepresented or inappropriately dismissed by Dr. Chan.

While the origin of the pandemic is still not known with certainty, Dr. Chan has identified her culprits without any actual evidence.

Florence Dbarre Paris The writer, an evolutionary biologist, is a senior researcher at the French National Center for Scientific Research.

To the Editor:

Based on the comments in response to this well-presented and compelling article, it appears that many still insist on putting their heads in the sand about the source of the Covid pandemic. They insist the article does not prove the origin of the pandemic to be the lab in Wuhan.

However, it should be noted that the headline of the article includes the word probably, which is probably as close as we will ever get to knowing the source of the pandemic, because the Chinese government certainly will never come clean about it if it is in any way at fault.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

See the rest here:

Opinion | Debating Covids Origins: A Lab or a Market? - The New York Times

Theres A New COVID Variant, KP.3 These Are The Symptoms – IFLScience

June 16, 2024

Its been over four years sinceCOVID-19 was officially declared a pandemic, and despite best efforts, the virus that causes it is still very much kicking about. Thats in large part thanks to it evolving into multiple different variants, the latest of which has been dubbed KP.3.

KP.3 is one of the FLiRT variants of SARS-CoV-2. These variants are rather less saucy than they sound; the name comes from the amino acid mutations theyve picked up in the spike protein, the part of the virus that latches onto the cells in our bodies and allows it to infect them.

The immune system can learn to recognize spike proteins either naturally or through vaccination and get rid of the virus, but by evolving into slightly different forms, the virus can evade destruction.

Thats why it seems like theres a new variant every other week KP.3 is the latest in a long line. In fact, FLiRT variants are all descended from another variant, JN.1, that popped up at the beginning of this year.

Until now the FLiRT variant KP.2 had taken over JN.1s top spot as the most dominant variant of the virus circulating in the US. However, according to predictions from the Centers for Disease Control and Prevention (CDC) which has a SARS-CoV-2 surveillance program tracking variants KP.3 has now taken over.

Currently, it is estimated that KP.3 viruses make up between 16% and 37% of all SARS-CoV-2 viruses in the United States, CDC Spokesperson Rosa Norman told USA Today.

But whilst it may be the most dominant, that doesnt necessarily mean therell be an uptick in cases. Most key COVID-19 indicators are showing low levels of activity nationally, therefore the total number of infections this lineage may be causing is likely low, Norman added.

That being said, with the increase in social gatherings often seen in the summer months, opportunities for the virus to spread and cause COVID-19 may also increase.

So, what are the signs of an infection with this new variant?

The CDCs list of possible symptoms for KP.3 is the same as those for JN.1:

Thats not an exhaustive list by any means. Symptoms may change with new COVID-19 variants and can vary by person, the CDC states. They can also appear up to two weeks after being exposed to the virus.

As for whether vaccines will be able to tackle the new variant, its hoped that updated vaccines set to be released in the fall pending FDA approval will do the job thanks to KP.3s lineage, as epidemiologist Adrian Esterman told Newsweek.

[T]here will be a new vaccine available around September, based on either JN.1 or one of the FLiRT subvariants, that will give much better protection."

Read the original:

Theres A New COVID Variant, KP.3 These Are The Symptoms - IFLScience

Are there any updates on COVID-19 we should know about? – Those Nerdy Girls

June 16, 2024

A: Here is whats new in the realm of COVID-19 right now:

In a nutshell:

There is a new COVID variant family called FLiRT that may lead to an increase in cases this summer.

Current vaccines will provide some protection against FLiRT variants.

Data so far does not suggest that FLiRT variants are more severe than prior variants. Data on long COVID risk is not available.

Current vaccines do wane over time, but continue to reduce disease severity. However, those over 65 or who are immunocompromised are eligible for a second dose this year to increase protection.

New updated vaccines targeting JN.1 will be available this fall.

There is a new variant family currently circulating, with individual variants known as KP.2, KP.3, and KP.1.1. Collectively, they have been named FLiRT. These variants are descendants of the omicron and JN.1 variants but have acquired new mutations that enable the virus to evade some prior immunity generated from vaccines or infection. Currently, data does not suggest a change in severity. It is unknown if the risk of long COVID is altered for these variants compared to earlier ones.

Dataso far suggests that immune cells generated from vaccines or prior infection can still target these variants, albeit less effectively.New dataalso shows that protection from the updated COVID-19 vaccines waned over the time since their rollout in Fall 2023, particularly in their protection against infection. However, they do still help decrease disease severity. The general population was only recommended to receive one updated COVID-19 vaccine for the 2023/2024 season. To enhance protection, individuals aged65 and olderor those immunocompromised are eligible to receive a second vaccine dose.

The FLiRT variants have been increasing in numbers globally but theCDC dashboardcurrently indicates low case numbers. However, certain regions are starting to see anuptick of cases, possibly signaling a summer wave.

Viruses mutate, so the emergence of new variants is not unexpected. This is why we are likely transitioning to an annual COVID-19 vaccine schedule that enables updated vaccines for new variants. The FDA met this week andvoted to proceedwith a new fall vaccinetargeting JN.1. Although FLiRT variants are somewhat different from JN.1, they share many similarities, so they will increase protection against these new variants. The updated vaccines are expected to be available sometime this fall. Exactly who will be eligible for the fall 2024 vaccine will be announced closer to rollout.

In the meanwhile, receiving a 2023/24 COVID vaccine, masking and other general infectious disease precautions can help mitigate your risk of getting sick this summer.

More:

Are there any updates on COVID-19 we should know about? - Those Nerdy Girls

COVID vaccines may have helped fuel rise in excess deaths – Houston Herald

June 16, 2024

COVID-19 vaccines could be partly to blame for the rise in excess deaths since the pandemic, scientists have suggested.

Researchers from The Netherlands analyzed data from 47 Western countries and discovered there had been more than three million excess deaths since 2020, with the trend continuing despite the rollout of vaccines and containment measures.

They said the unprecedented figures raised serious concerns and called on governments to fully investigate the underlying causes, including possible vaccine harms.

Writing in the BMJ Public Health, the authors from Vrije Universiteit, Amsterdam, said: Although COVID-19 vaccines were provided to guard civilians from suffering morbidity and mortality by the COVID-19 virus, suspected adverse events have been documented as well.

Both medical professionals and citizens have reported serious injuries and deaths following vaccination to various official databases in the Western World.

They added: During the pandemic, it was emphasised by politicians and the media on a daily basis that every COVID-19 death mattered and every life deserved protection through containment measures and COVID-19 vaccines. In the aftermath of the pandemic, the same morale should apply.

The study found that across Europe, the U.S. and Australia there had been more than one million excess deaths in 2020, at the height of the pandemic, but also 1.2 million in 2021 and 800,000 and 2022 after measures were implemented.

Researchers said the figure included deaths from COVID-19, but also the indirect effects of the health strategies to address the virus spread and infection.

They warned that side effects linked to the COVID vaccine have included ischemic stroke, acute coronary syndrome and brain hemorrhage, cardiovascular diseases, coagulation, hemorrhages, gastrointestinal events and blood clotting.

German researchers have pointed out that the onset of excess mortality in early 2021 in the country coincided with the rollout of vaccines, which the team said warranted further investigation.

However, more recent data regarding side-effects has not been made available to the public, with countries keeping their own individual databases of harms, which rely on self-reporting by the public and doctors, the experts warned.

Researchers said that it was likely that the impact of containment measures, restricted healthcare and socioeconomic upheaval during the pandemic had contributed to deaths, although accepted that was difficult to prove.

Gordon Wishart, chief medical officer at Check4Cancer, and visiting professor of cancer surgery at Anglia Ruskin University, warned repeatedly that delaying cancer diagnosis would lead to deaths.

It was predicted early in the lockdown period that limited access to healthcare for non-COVID conditions would lead to delays in the diagnosis and treatment of time-critical conditions such as cancer, cardiac disease, diabetes and dementia and that this would lead to excess deaths from these conditions, he said.

NHS England data shows that per 100,000 people the cancer incidence was 521 in the pre-lockdown year, then fell to 456 in 2020/2021 suggesting around 45,000 cancers were missed in the first pandemic year.

The incidence rate rose to 540 per 100,000 the following year suggesting many cancers were diagnosed late, when treatment would be less effective.

Speaking about the potential for vaccine harm, Wishart added: The authors are correct to point out that many vaccine-related serious adverse events may have been unreported, and point to the fact that the simultaneous onset of excess mortality and COVID vaccination in Germany is worthy of further investigation on its own. The paper provides more questions than answers, but it is hard to disagree with their conclusion that further analysis is required to understand the underlying causes of excess mortality to better prepare for the future management of pandemic crises.

YAHOO NEWS

Read this article:

COVID vaccines may have helped fuel rise in excess deaths - Houston Herald

Intranasal COVID-19 vaccine headed to clinical trials – University of Georgia

June 16, 2024

University of Georgia-based startup CyanVac LLC received federal funding to support a comparative Phase 2b clinical trial of CVXGA, the companys intranasal vaccine candidates designed to protect against COVID-19.

As part of the award from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services (HHS), CyanVac will sponsor a randomized, double-blind Phase 2b study with 10,000 participants to compare the efficacy and safety of the intranasal vaccine against an FDA-approved mRNA-based COVID-19 vaccine.

The new vaccine is based on a viral delivery platform developed by He containing modified strains of parainfluenza virus 5, which causes kennel cough in dogs but is harmless to humans.

CyanVac was founded by Biao He, Regents Entrepreneur,Fred C. Davison Distinguished University Chair in Veterinary Medicine and a faculty member in UGAs College of Veterinary Medicine (CVM). He served on a White House panel to advise on the future of COVID-19 vaccines and was named both UGA Inventor and Entrepreneur of the Year.

We are very excited about this opportunity to test a novel intranasal COVID vaccine whose technology platform has been developed at UGA, said He, who is based in UGAs Department of Infectious Diseases. The name of our vaccineCVXGAis a tribute to UGA and CVM whose support over the years made this possible.

Project NextGens goal is to advance new, innovative vaccines and therapeutics that provide longer lasting and more durable protection against COVID-19. The award is one of the first made through the Rapid Response Partnership Vehicle, a consortium funded by the HHS Biomedical Advanced Research and Development Authority (BARDA) to accelerate product and technology development.

The Phase 2b study, which will begin this fall, will be carried out by BARDAs Clinical Studies Network, focusing on evaluating the vaccine in a subset of participants who are at a higher risk of severe disease.

Go here to see the original:

Intranasal COVID-19 vaccine headed to clinical trials - University of Georgia

MDs’ One-Word Summary of Long COVID Progress: ‘Frustration’ – Medscape

June 12, 2024

Stuart Malcolm, MD, a primary care physician who practices in Oregon and northern California, started seeing patients with long COVID early in the pandemic. Back then, he was frustrated by the obstacles and lack of standard diagnostic tests and treatments. Four years later, well, he still is.

"Something I learned the last few years is the logistics to get people care is really, really hard," he said. "There's a lot of frustration. It's mostly frustration."

For long COVID doctors and patients, there has been little to no progress addressing the challenges, leaving many discouraged. Researchers and clinicians now have a greater understanding of what health agencies formally call post-COVID condition, but the wide spectrum of symptoms, slow progress in launching pharmacologic clinical trials, and the research toward understanding the underlying causes mean standardized diagnostic tests and definitive treatments remain elusive.

"The frustration is that we aren't able to help everyone with our current knowledge base. And I think the frustration lies not just with us physicians but also with patients because they're at the point where if they tried everything, literally everything and haven't gotten better," said Zijian Chen, MD, director of the Mount Sinai Center for Post-COVID Care in New York City.

Between 10% and 20%of the estimated hundreds of millions of people infected worldwide with SARS-CoV-2 in the first 2 years went on to develop long-term symptoms. While many recover over time, doctors who have treated long COVID since 2020 said they see some patients still wrestling with the condition after 4 years.

The latest Centers for Disease Control and Prevention Household Pulse Survey, taken between March 5 and April 1, 2024, estimated that nearly 7% of the adult population more than 18 million people currently have long COVID. Data from other countries also suggest that millions have been living with long COVID for years now, and hundreds of thousands have seen their day-to-day activities significantly affected.

There is an urgent need for more funding, long COVID clinicians, multidisciplinary clinics, and education for nonlong COVID physicians and specialists, doctors said. Instead, funding remains limited, clinics are closing, wait times are "horrendously long," patients are left in limbo, and physicians are burning out.

"What's changed in some ways is that there's even less access to COVID rehab, which sounds crazy because there was very little to begin with," said Alexandra Rendely, MD, a physical medicine and rehabilitation physician with the interdisciplinary Toronto Rehab, a part of the University Health Network of teaching hospitals in Toronto, Ontario, Canada.

"Patients are still being diagnosed every day, yet the resources available are becoming less and less."

COVID-19 money earmarked during the pandemic was mostly limited to temporary emergency measures. As those funds dwindled, governments and institutions have decreased financial support. The Long COVID Moonshot campaign, organized by patients with long COVID, is pushing Congress to support $1 billion in annual research funding to close the financial chasm.

While long COVID clinics have come a long way in helping patients, gaps remain. Doctors may be unwilling to prescribe off-label treatments without proper clinical trials due to the potential risks and liabilities involved or due to the controversial or unconventional nature of the therapies, said Malcolm, who left his primary care practice more than 2 years ago to focus on long COVID.

In the absence of standard treatments, Malcolm and other doctors said they must take a trial-and-error approach in treating patients with long COVID that centers on addressing symptoms and not the underlying condition.

"There are actually a lot of treatments and a lot of them are not curative, but they can help people," he said.

Malcolm, who is a medical director at Real Time Health Monitoring, a private clinic in the San Francisco Bay Area that specializes in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), said it was important for him to be with a clinical team that understood and was supportive of his treatment decisions and was able to offer clinical support for those treatments if needed.

For physicians looking for clinical data before prescribing certain medications, the wait may be long. More than $1.5 billion in US federal funding has been earmarked to study long COVID, but the National Institutes of Health (NIH) has faced criticism from patients and scientists alike for its slow progress and emphasis on observational studies instead of research that could unravel the biological roots of long COVID. Among the clinical trials announced by the NIH's RECOVER initiative, only a handful involve studying pharmaceutical treatments.

A 2023 editorial published in The Lancet called out the "dismal state of clinical research relative to the substantial burden of [long COVID]" and said, "we are clearly lacking tested pharmacological interventions that treat the underlying pathophysiology." At the time of publication, it noted that of the 386 long COVID trials listed on ClinicalTrials.gov, only 12 were actually testing pharmacologic interventions.

There are also diagnostic and insurance barriers. The specialized tests that can detect long COVID anomalies are neither commonly known by primary care practitioners nor easily requested at the local lab, can be expensive, and are typically not covered by insurance, Malcolm explained.

Patients with long COVID also have the added barrier of being unable to advocate as easily because of their energy limitations, doctors said. Patients may appear outwardly fine, but fatigue and brain fog are among the many problems that cannot be measured in appearances. The condition has upended lives, some losing jobs, even homes, and the mental toll is why there is a "not insignificant" suicide rate.

Charlie McCone, 34, used to be a tennis player and an active musician. But he's spent the past 4 years mostly housebound, grappling with the aftermath of a SARS-CoV-2 infection he contracted in March 2020. He went from biking daily to work 10 miles and back to having at most 2 hours of energy per day.

In the first year alone, McCone saw more than two dozen doctors and specialists. The conditions now associated with long COVID, like ME/CFS, mast cell activation syndrome (a condition in which a patient experiences episodes of allergic symptoms such as hives, swelling, low blood pressure, and difficulty breathing), or dysautonomia (conditions that affect the autonomic nervous system, which controls automatic processes in the body) were not on physicians' radars.

Then in 2021, he became bedbound for more than half a year after a Delta variant reinfection. He developed neurologic symptoms, including incapacitating fatigue, post-exertional malaise (where symptoms worsened after minimal physical or mental activity), left-sided weakness, and cognitive impairment. He stopped working altogether. But the worst was the shortness of breath he felt 24/7, even at rest. A battery of lab tests revealed nothing abnormal. He tried numerous drugs and the classic respiratory treatments.

McCone eventually connected with Malcolm over X and developed what he describes as an effective patient-doctor collaboration. When studies came out suggesting microclots were a common issue with patients with long COVID and positive outcomes were reported from anticoagulant therapy, they knew it could be one of the answers.

"After 3 weeks on [the antiplatelet drug], I was like, oh my god, my lungs are finally opening up," said McCone. He has taken the medication for more than a year and a half, and some days he doesn't even think about his respiratory symptoms.

"That trial-and-error process is just really long and hard and costly," said Malcolm.

Today, fatigue and cognitive stamina are McCone's main challenges, and he is far from recovered.

"[I had a] very fulfilling, happy life and now, it's hard to think about. I've come a long way with my mental health and all this, but I've lost 4 years," McCone said. "The prospect of me being here when I'm 40 seems very realso it's pretty devastating."

Despite the daunting obstacle, doctors said the science has come a long way for a new disease. We now know long COVID is likely caused by a combination of triggers, including viral reservoir in the tissue, inflammation, autoimmunity, and microclots; severity of infection is not necessarily an accurate risk factor predictor long COVID can strike even those who had a mild infection; upward of 200 symptoms have been identified; and we know more about potential biomarkers that could lead to better diagnostic tools.

Unlike many other diseases and conditions with standard treatment protocols, long COVID treatments are typically aimed at addressing individual symptoms.

"It is very detailed and individualized to the patient's specific symptoms and to the patient's specific needs," Rendely said. Symptoms can also fluctuate, relapse, or wax and wane, for example, so what ails a patient at their first doctor's appointment could be completely different at the next appointment 2 months later.

Doctors are still hopeful the RECOVER research, which includes trials that look at autonomic and cognitive dysfunctions, will pave the way for more effective long COVID therapies. In Canada, Rendely is also eying the RECLAIM trial that is currently testing the effectiveness of pentoxifylline, which helps blood flow, and ibudilast, an anti-inflammatory drug.

Doctors are also hopeful when they see patients who have made "tremendous gains" or even full recoveries through their clinics. "It's a new diagnosis, so I always tell my patients to think of this as a journey because I'm learning along with you," said Jai Marathe, MD, an infectious disease physician at Boston Medical Center and an assistant professor of infectious diseases at Boston University Chobanian & Avedisian School of Medicine.

"Now we have 4 years of experience, but at the same time, no two long COVID patients are alike."

Long COVID has also changed the way physicians view healthcare and how they practice medicine.

"I am a completely different person than I used to be because of this illness, and I don't even have it. That is how profoundly it has affected how I view the universe," said Malcolm. "I've been doing this for 4 years, and I'm very hopeful. But I don't think about this in terms of months anymore. I think about this in terms of years."

Here is the original post:

MDs' One-Word Summary of Long COVID Progress: 'Frustration' - Medscape

Page 20«..10..19202122..3040..»